Key Highlights

● DexCom rose on Friday, October 30, 2026, against a falling market.

● Adjusted Earnings of 73 cents a share beat the 67 to 68 cents estimate.

● The company authorized up to $1 billion in share repurchases.

● Full-year Revenue guidance of $5.20 billion to $5.25 billion bracketed consensus.

DexCom (NASDAQ:DXCM) rose on Friday, October 30, 2026, rallying against a falling market after third-quarter results topped expectations. The San Diego-based maker of continuous glucose monitoring systems for people with diabetes reported adjusted earnings of 73 cents a share, ahead of the 67 to 68 cents analysts had expected. Revenue reached $1.344 billion, above the $1.33 billion consensus.

The company also authorized up to $1 billion in share buybacks. The stock was solidly higher at midday, according to market data.

Guidance close to the consensus

DexCom set its full-year 2026 revenue guidance at $5.20 billion to $5.25 billion, a range that brackets the $5.23 billion analysts had forecast. That outlook did not dramatically reset expectations, but paired with a quarterly beat and a large repurchase plan, it was enough to put the stock among Friday's gainers.

Health care's record day

DexCom's rally came as the health care sector hit a record high, according to market data. Investors rotated out of semiconductors and megacap technology and into defensive groups including health care, consumer staples, utilities and energy. Six of the S&P 500's 11 sectors finished higher.

Other medical names delivered big moves in both directions. Regeneron Pharmaceuticals (NASDAQ:REGN) was the S&P 500's top gainer after third-quarter revenue of $5.12 billion beat the $4.54 billion forecast. Gilead Sciences (NASDAQ:GILD) climbed on an earnings beat and raised product sales guidance. But device maker Stryker (NYSE:SYK) fell after its third-quarter revenue and adjusted earnings missed forecasts and it cut its organic growth outlook, and Canaccord downgraded the shares to Hold from Buy. Illumina (NASDAQ:ILMN) also dropped sharply after revenue came in below consensus.

That split showed investors were not buying health care indiscriminately. Companies that beat were rewarded, and those that missed were punished even in a favored sector.

The market around it

The broader tape was rough. The S&P 500 fell 140.32 points to 7,580.07, and the Nasdaq Composite tumbled 747.73 points to 25,437.00, its worst day since June 5. The Nasdaq-100, which includes DexCom, closed at 28,384.85. The Dow Jones Industrial Average lost 572.25 points to 51,770.31.

Intel (NASDAQ:INTC)'s weak fourth-quarter guidance and cash-burn warning drove a collapse in chipmakers, and Amazon (NASDAQ:AMZN)'s negative trailing free Cash Flow added to concern about AI spending. An Investment strategist said: "The earnings bar is very high." DexCom's third-quarter numbers cleared it on both earnings and revenue.

The macro backdrop remained a consideration. The Federal Reserve held its benchmark rate range steady this week in a 10-2 vote, and markets have priced in a December rate increase. Chair Kevin Warsh said: "The Committee will deliver price stability." On Friday, St. Louis Fed President Alberto Musalem went further: "I judge that additional firming of Monetary Policy will be necessary, and soon."

What to watch

Investors will watch how quickly DexCom puts its buyback authorization to work and whether fourth-quarter revenue keeps the company on track for its $5.20 billion to $5.25 billion full-year range. Any update on Demand for its glucose monitors will be closely followed.

For the sector, the question is whether health care's run continues. The midterm elections on Tuesday, November 3, and the October jobs report on Friday, November 6, could shift the rotation that lifted defensive stocks, and drugmaker Pfizer (NYSE:PFE) reports on Tuesday. Health care investors will be watching to see whether the record high marks a lasting shift in market leadership.